European Archives - Page 693 of 1303 - European Medical Journal

Reacting to supply chain risks

The pharmaceutical supply chain is vulnerable to adverse events, and the pandemic has served as a reminder of how these networks can be tested. The industry has learned tough lessons from COVID-19 that must be translated into modernisation and improvements

Wayne Best, VMLY&R

Innovative tech, pharma supply chains and more

Marc and Helena chat with Wayne Best, Chief Creative Officer, VMLY&R, about his ‘I Will Always Be Me’ project for patients with motor neurone disease. Listen now!

EULAR Podcast Highlights: COVID-19, rheumatoid arthritis and ankylosing spondylitis

A review of the latest and most pertinent information from EULAR 2021 regarding COVID-19 for patients with rheumatic musculoskeletal…

EULAR Podcast Highlights: Latest treatment options for Psoriatic Arthritis

The novel data presented at EULAR 2021 highlights the latest treatment options and safety aspects for patients with psoriatic arthritis…

Spoonful of technology: February 2023

GOLD reviews the top stories in health technology from the past few months, highlighting how tech is changing treatment landscapes and patient experiences.

Disability and Death Risk Increased in COVID-19-Associated Stroke

Many patients with COVID-19 present at the hospital with symptoms of acute ischaemic stroke, caused by a sudden blockage of blood flow…

Could Smartphones Diagnose and Track Neurological Conditions?

Allow neurologists and patients to capture important clinical data using readily available technology, such as smartphones and tablets…

Dermatology CP

Paget Disease of Skin Secondary to Urothelial Carcinoma

Currently, the exact mechanism underlying EMPD is unknown, but two widely known theories exist, namely the epidermotropic and transformation theories.

EMJ Hematology 10 [Supplement 2] 2022

EXPERT discussion from a satellite symposium presented at the European Hematology Association (EHA) Virtual Congress 2021 focused on myelodysplastic syndrome (MDS), a heterogeneous group of myeloid malignancies characterised by ineffective haematopoiesis, progressive bone marrow failure, and increased risk of acute myeloid leukaemia evolution.

Idarucizumab in Emergent Pericardiocentesis

A 71-year-old male with atrial fibrillation (AF) was admitted to the authors’ emergency department with fever, progressive dyspnoea…